Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $14.10 HKD
Change Today 0.00 / 0.00%
Volume 84.3K
As of 4:01 AM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

shandong luoxin pharmaceut-h (8058) Snapshot

Open
$14.02
Previous Close
$14.10
Day High
$14.18
Day Low
$14.00
52 Week High
11/14/14 - $18.38
52 Week Low
05/9/14 - $8.65
Market Cap
8.6B
Average Volume 10 Days
268.0K
EPS TTM
$0.73
Shares Outstanding
164.6M
EX-Date
06/10/15
P/E TM
15.5x
Dividend
$0.30
Dividend Yield
2.64%
Current Stock Chart for SHANDONG LUOXIN PHARMACEUT-H (8058)

Related News

No related news articles were found.

shandong luoxin pharmaceut-h (8058) Related Businessweek News

No Related Businessweek News Found

shandong luoxin pharmaceut-h (8058) Details

Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. is engaged in the manufacture and sale of pharmaceutical products in the People’s Republic of China. It is also involved in the manufacture and wholesale of biochemical products and Chinese medicine. The company was formerly known as Shandong Luoxin Pharmacy Stock Co., Ltd. and changed its name to Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. in August 2014. The company was founded in 1995 and is based in Linyi, China. Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. is a subsidiary of Luoxin Pharmacy Group Co., Ltd.

Founded in 1995

shandong luoxin pharmaceut-h (8058) Top Compensated Officers

Chief Executive Officer, Head of Research & D...
Total Annual Compensation: CNY120.0K
Executive Director
Total Annual Compensation: CNY48.0K
Secretary of the Board and Executive Director
Total Annual Compensation: CNY60.0K
Vice General Manager of Production Department...
Total Annual Compensation: CNY60.0K
Manager of Bulk Medicine Workshop and Supervi...
Total Annual Compensation: CNY60.0K
Compensation as of Fiscal Year 2013.

shandong luoxin pharmaceut-h (8058) Key Developments

Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. Reports Consolidated Cash Flow Results for the Year Ended December 31, 2014

Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. reported consolidated cash flow results for the year ended December 31, 2014. For the year, net cash generated from operating activities was RMB 423,681,000 against RMB 79,452,000 a year ago. Purchase of property, plant and equipment was RMB 66,373,000 against RMB 82,093,000 a year ago.

Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. Recommends Final Dividend for the Year Ended December 31, 2014; Reports Audited Consolidated Earnings Results for the Year Ended December 31, 2014

The Board of Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. has recommended the payment of a final dividend of RMB 0.3 per share in respect of the year ended December 31, 2014. Subject to the approval of shareholders at the forthcoming AGM, the dividend cum-date and ex-date will be June 9, 2015 and June 10, 2015 respectively. The registers of members of the company for entitlement of dividend will be closed from June 12, 2015 to June 17, 2015 (both days inclusive). The Group will strictly comply with the relevant PRC tax laws and regulations to withhold for payment such appropriate income tax and the final dividend will only be payable to the shareholders whose names appear on the Group's H-share register of members on June 17, 2015. The company reported audited consolidated earnings results for the year ended December 31, 2014. For the year, the company's turnover amounted to approximately RMB 2,766,788,000, representing an increase of approximately 9.38% as compared with RMB 2,529,464,000 for the year ended 31 December 2013. Profit attributable to shareholders amounted to approximately RMB 443,553,000, representing an increase of approximately 3.49% as compared with RMB 428,585,000 for the year ended 31 December 2013. Profit before taxation was RMB 527,925,000 compared to RMB 503,487,000 reported a year ago. Profit for the year attributable to owners of the company was RMB 443,553,000 or RMB 0.728 per basic and diluted share compared to RMB 428,585,000 or RMB 0.703 per basic and diluted share reported a year ago. The increase was attributable to the Group's launch of high value-added products, upgrade of product portfolio and acceleration of the development of its sales network to increase the market share of its products thereby boosting its turnover.

Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. to Report Fiscal Year 2014 Results on Mar 10, 2015

Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. announced that they will report fiscal year 2014 results on Mar 10, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
8058:HK $14.10 HKD 0.00

8058 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 8058.
View Industry Companies
 

Industry Analysis

8058

Industry Average

Valuation 8058 Industry Range
Price/Earnings 15.5x
Price/Sales 2.5x
Price/Book 2.9x
Price/Cash Flow 15.5x
TEV/Sales 2.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SHANDONG LUOXIN PHARMACEUT-H, please visit www.luoxin.cn. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.